 |
|
|
| |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable
Tolerability to Efavirenz/Emtricitabine/Tenofovir DF and to Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir
DF in Patients ≥50 Years at Week 96
|
| |
| |
Studies 102 and 103 - Age Sub-analysis
Reported by Jules Levin
53rd International Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Denver, CO, USA
Sept 10-13, 2013
J Gallant1, D Hardy2, F Bredeek3, K Workowski4, W Towner5, L Dau6, H Liu6, J
Curley6, M Rhee6, D Piontkowsky6, J Szwarcberg6
1Southwest CARE Center, Santa Fe, NM, 2David Geffen School of Medicine-UCLA, Los Angeles, CA, 3Metropolis Med Group, San Francisco, CA, 4Emory Univ, Atlanta, GA, 5Kaiser Permanente, Los Angeles, CA, 6Gilead Sciences, Foster City, CA
|
| |
|
|
|
|
|
